Gene-Based drug study aims to personalize cancer treatment
NCT ID NCT02680795
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This early-phase study looked at how the cancer drug belinostat is processed in the body and its safety in 17 patients with advanced solid tumors or blood cancers. Participants were grouped by their UGT1A1 gene type (common or variant) to see if genetic differences affect drug breakdown. The goal was to gather information for future dosing guidance, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
John Wayne Cancer Institute @ Providence Saint John's Health Center
Santa Monica, California, 90404, United States
-
The Oncology Institute of Hope and Innovation
Whittier, California, 90603, United States
Conditions
Explore the condition pages connected to this study.